Check for updates

OPEN ACCESS

EDITED BY Iokfai Cheang, Nanjing Medical University, China

REVIEWED BY Sibo Wang, Nanjing Medical University, China Songfeng Zhao, Central South University, China

*CORRESPONDENCE Shilong Zhong ⊠ shz2020@qq.com

[†]These authors share first authorship

RECEIVED 26 January 2024 ACCEPTED 20 May 2024 PUBLISHED 05 June 2024

CITATION

Chen K, Li S, Xie Z, Liu Y, Li Y, Mai J, Lai C, Wu Q and Zhong S (2024) Association between oxidative balance score, systemic inflammatory response index, and cardiovascular disease risk: a cross-sectional analysis based on NHANES 2007–2018 data. *Front. Nutr.* 11:1374992. doi: 10.3389/fnut.2024.1374992

COPYRIGHT

© 2024 Chen, Li, Xie, Liu, Li, Mai, Lai, Wu and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Association between oxidative balance score, systemic inflammatory response index, and cardiovascular disease risk: a cross-sectional analysis based on NHANES 2007–2018 data

Kai Chen^{1,2,3†}, Senlin Li^{1,2,3†}, Zhipeng Xie^{1,2,3}, Yingjian Liu^{1,2,3}, Yangchen Li^{1,2,3}, Jinxia Mai^{2,3}, Chengyang Lai^{1,2,3}, Qili Wu^{1,2,3} and Shilong Zhong^{1,2,3}*

¹School of Medicine, South China University of Technology, Guangzhou, Guangdong, China, ²Department of Pharmacy, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China, ³Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Background: There is limited research on the relationship between Systemic Oxidative Stress (SOS) status and inflammatory indices. Adding onto existing literature, this study aimed to examine the association between dietary Oxidative Balance Score (OBS) and lifestyle OBS (which make up the overall OBS), and Cardiovascular Disease (CVD) prevalence at different Systemic Immune Inflammation Index (SII) and Systemic Inflammatory Response Index (SIRI) levels.

Methods: This study involved 9,451 subjects selected from the National Health and Nutrition Examination Survey (NHANES) 2007–2018. The OBS comprised 20 dietary and lifestyle factors. Statistical methods included Weighted Linear Regression Analysis (WLRA), Logistic Regression Analysis (LRA), Sensitivity Analysis (SA), and Restricted Cubic Spline (RCS) analysis.

Results: The multivariate WLRA revealed that OBS was significantly negatively correlated with both SII ($\beta = -5.36$, p < 0.001) and SIRI ($\beta = -0.013$, p < 0.001) levels. In SA, removing any single OBS component had no significant effect on the WLRA results of SII and SIRI. Further subgroup analyses revealed that OBS was more impactful in lowering SII in women than in men. Additionally, OBS was more significantly negatively correlated with SII and SIRI in the low-age group than in the high-age group. Moreover, RCS analysis confirmed this linear relationship. Compared to dietary OBS, lifestyle OBS exerted a more significant effect on Coronary Artery Disease (CAD) (OR: 0.794, p = 0.002), hypertension (OR: 0.738, p < 0.001), Congestive Heart Failure (CHF) (OR: 0.736, p = 0.005), Myocardial Infarction (MI) (OR: 0.785, p = 0.002), and stroke (OR: 0.807, p = 0.029) prevalence. Furthermore, SIRI exhibited a significant interaction in the relationship between overall OBS, dietary OBS, and CHF (*P for interaction* < 0.001). On the other hand, SII had a significant interaction in the relationship between OVER (DR) and MI (*P for interaction* < 0.05).

Conclusion: OBS, including lifestyle and dietary OBS, were significantly negatively associated with SII and SIRI. Higher lifestyle OBS was associated with reduced risks of CAD, hypertension, CHF, MI, and stroke.

Introduction

Cardiovascular Disease (CVD) encompasses a wide range of diseases that affect the heart, blood vessels, or pericardium, including but not limited to Coronary Artery Disease (CAD), Angina Pectoris (AP), and stroke (1, 2). According to research, CVD is a leading cause of death worldwide (3), as well as in European Society of Cardiology (ESC) member countries (4). Furthermore, CVD prevalence in China has steadily increased over the years, reported to have reached 94 million in 2016 (5). These findings make CVD treatment and prevention a valuable research focus.

Oxidative Stress (OS), an imbalance between Reactive Oxygen Species (ROS) production capacity and the antioxidant capacity (6, 7), is one of the risk factors for CVD (8, 9). According to research, lifestyle and dietary compositions can alter the human body's OS state (10). In this regard, Oxidative Balance Score (OBS), a metric that assesses lifestyle and dietary compositions, could be employed to obtain different behavioral scores and determine the degree of antioxidant exposure (10, 11). A recent Korean cohort study involving 5,181 participants found a negative correlation between OBS and the likelihood of new-onset hypertension (12). Notably, OS and inflammation are often comorbid. Studies in the US general population have revealed a U-shaped relationship between the inflammation SII level and all-cause mortality in CAD\AP\Myocardial Infarction (MI) patients (13, 14). Furthermore, unhealthy sleep behaviors and OBS may jointly affect CVD risk via specific pathways (15). Systemic Immune-Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI) are new inflammatory markers with a strong relationship with CVD (16). In obese individuals, SIRI and SII are independent risk factors for total CVD mortality (17), and high SII levels are closely associated with CVD (18).

Although the OBS-CVD association has been reported multiple times, the relationship between CVD and both lifestyle OBS and dietary OBS remains unclear. It is also unclear whether new findings will emerge from these two scoring standards and whether the level of SII will affect OBS and CVD. Therefore, this study examined the association between OBS and SII/SIRI, as well as the relationship between OBS and CVD under high and low SII/SIRI conditions using a representative sample of the US population obtained from the National Health and Nutrition Examination Survey (NHANES) 2007–2018.

Materials and methods

Study subjects and data sources

The NHANES project is a nationwide survey designed to assess the health and nutritional status of adults and children in the US (19, 20). Specifically, it integrates questionnaire surveys and physical examinations to address health issues among different populations. The survey results can be utilized to determine the incidence rates and risk factors for major illnesses and evaluate the US population's nutritional status and its relationship with health promotion and disease prevention.

Herein, the inclusion and exclusion criteria were implemented as follows: (1) First, 51,472 participants with dietary OBS components were recruited in six two-year survey cycles (2007 to 2008, 2009 to 2010, 2011 to 2012, 2013 to 2014, 2015 to 2016, and 2017 to 2018); (2) Subsequently, 40,287 participants with missing lifestyle OBS components were excluded [comprising 23,379, 12,315, 4,549, and 44 participants with unavailable physical activity data, missing alcohol data, cotinine levels exceeding the detection limit, and unspecified Body Mass Index (BMI) data, respectively]; (3) Following that, 45 participants with missing platelet, neutrophil, monocyte, and lymphocyte count data were excluded; and (4) Finally, 83 pregnant individuals, 767 cancer patients, and 839 participants with extreme energy intake (men, total energy intake <800 or>4,200 kcal/day; women, total energy intake <500 or > 3,500 kcal/day) were excluded. As a result, 9,451 participants were included in the final analysis (Figure 1).

The National Centre for Health Statistics (NCHS) Ethics Review Board approved the NHANES project, and participants gave written informed consent. Further details on the NHANES project can be found on its official website.

Exposure definition

The OBS was determined based on previous research. Herein, the OBS comprised 16 dietary components and 4 lifestyle components, further categorized into pro-oxidant (5 factors) and antioxidant (15 factors) subgroups (21). The scores of each variable were added to determine the total OBS, with higher scores indicating greater exposure to antioxidants.

For a comprehensive understanding of the US population's dietary intake, trained dietary interviewers assessed the nutritional components in NHANES data collected through face-to-face 24 h dietary recall interviews with participants of all ages. The interviewers were fluent in Spanish and English, and the interviews were conducted in private rooms at NHANES' Mobile Examination Centre (MEC). Each MEC dietary interview room contained a standard set of measurement guides. These components do not represent any particular food and were used to assist respondents in reporting the amount of food consumed accurately. This set of measurement guides was developed specifically for the current NHANES environment, targeting the non-institutionalized US civilian population. The NCHS was consulted for sample design and data collection, and the United States Department of Agriculture (USDA) Food Survey Research Group (FSRG) was consulted for dietary survey methodology design and subsequent data processing and review.

Alcohol consumption, smoking, BMI, and physical activity were included in the analysis of Lifestyle OBS indicators. Alcohol consumption was defined as the average number of drinks consumed per day over the previous 12 months during the days when participants



consumed alcohol, including any alcoholic beverage. Cotinine, the primary metabolite of nicotine, can be quantified in serum, urine, or saliva and could serve as a marker of active smoking as well as exposure to Environmental Tobacco Smoke (ETS) or 'passive smoking' given its longer half-life in the blood compared to nicotine. Furthermore, plasma cotinine levels were previously selected for quantitative exposure assessment studies (22). On the other hand, BMI was calculated by dividing weight (Kg) by height (m²). Physical activity data were obtained from the NHANES Physical Activity Questionnaire (PAQ), administered by trained interviewers in participants' homes using the Computer-Assisted Personal Interview (CAPI) system. The questionnaire encompassed work-related activities (including vigorous- and moderate-intensity activities) and leisure-time physical activities (such as walking or cycling and other vigorous land moderate leisure-time activities). Physical activity calculations were based on methodologies established in previous research. Specifically, physical activity was computed as the product of the frequency of each physical activity per week, with the duration of each physical activity, and then with the Metabolic Equivalent (MET) score (21).

Participants were categorized into two groups based on their SII weighted medians: Low and high. All OBS components within each group were further classified into three subgroups based on their weighted distribution (from the first to the third quartile). Antioxidants were assigned scores ranging from 0 to 2, whereas oxidants were scored reversely, with 2 and 0 representing the lowest and highest activity levels, respectively (Supplementary Table S1). Supplementary Table S2 shows the categorization of OBS components in mid-subjects based on the SIRI-weighted median.

Definitions of SII and SIRI

The Beckman Coulter DxH 800 instrument was used in the NHANES MEC to perform a Complete Blood Count (CBC) on blood

samples, providing a blood cell count for all participants. Lymphocytes, neutrophils, monocytes, and platelets were counted in 10³ cells/uL units. The SII and SIRI values were calculated using previously established formulas (23, 24), which are as follows.

SII = (platelet count × neutrophil count) / lymphocyte count

SIRI = (neutrophil count × monocyte count) / lymphocyte count

Outcome definitions

The diagnosis of AP, CAD, (Congestive Heart Failure) CHF, MI, and stroke was confirmed by self-reported physician diagnosis in the questionnaire. Hypertension was defined as a self-reported physician diagnosis of hypertension, use of antihypertensive medication, or meeting the combined Systolic Blood Pressure (SBP) \geq 140 mmHg/Diastolic Blood Pressure (DBP) \geq 90 mmHg criteria (25).

On the other hand, CVD patients were defined as those with a confirmed diagnosis of at least one of the following: AP, CAD, hypertension, CHF, MI, and stroke.

Other variables of interest

Herein, age, race/ethnicity, sex, and energy intake were included as covariates. Education level was also incorporated as a subgroup analysis. Race/ethnicity was classified into various categories, including non-Hispanic White, non-Hispanic Black, other Hispanic, Mexican American, and other race/ethnicity. On the other hand, education level was categorized as high school (comprising high school diploma or general equivalency or some college/associate's degree), \leq high school (including <9th grade, 9th through to 11th grades, and 12th grade without a diploma), and \geq high school (comprising a college degree or higher). Biochemical parameters were assessed following a rigorous approach outlined in the NHANES Laboratory/Medical Technologist Procedure Manual (CDC: NHANES Laboratory/ Medical Technologists Procedures Manual, Atlanta, GA, CDC, 2001).

Statistical analysis

We first downloaded NHANES data from 2007 to 2018 that were relevant to this study. Given the complex sampling design of NHANES (i.e., 1/6 * WTDRD1), individual sample weights were determined based on the NHANES recommended one-day sample weights for diet (WTDRD1) records. During baseline data analysis, the normal distribution of the continuous variables was examined, and all were non-normal continuous variables. Non-normal continuous variables were expressed as medians or Interquartile Ranges (IQR) and categorical variables were presented as unweighted numbers (weighted %).

Weighted Linear Regression Analysis (WLRA) was used to examine the relationship between overall OBS, lifestyle OBS, dietary OBS, and SII/SIRI levels. Further subgroup analyses were performed according to sex, age, and education. Furthermore, Restricted Cubic Spline (RCS) analysis was used to test for non-linear trends between variables based on the linear regression results (26). Logistic Regression Analysis (LRA) was used to compare the associations between OBS and CVD at different SII/ SIRI levels. Three models were used. Model 1, a crude model without additional adjustment for covariates; Model 2, which was adjusted for age, sex, and race/ethnicity; and Model 3, which was adjusted for age, sex, race/ethnicity, and energy intake. All regression analyses included survey weights. Sensitivity Analyses (SA) involved recalculating the OBS through selective deletion of individual OBS components, pooling the remaining OBS components, and then analyzing the correlation between the new OBS and SII/SIRI levels.

All data cleaning and processing procedures were performed in R (version 4.2.1). Furthermore, all analyses were two-tailed, and results with p < 0.05 were considered statistically significant.

Results

Baseline characteristics of the study population

Table 1 shows the baseline characteristics of individuals grouped by OBS quartiles (Median age = 39 years; Males = 57%). Furthermore, the majority were non-Hispanic White (66.6%), and the weighted CVD prevalence was 31.3%, with a lower prevalence in participants in the highest OBS quartile compared to those in the lowest OBS quartile (p < 0.001). Additionally, participants in the highest OBS quartile had a significantly lower hypertension prevalence than those in the lowest OBS quartile (p = 0.001). The OBS groups also exhibited statistically significant differences in gender and ethnicity. Overall, SII/SIRI levels decreased gradually with increasing OBS. The weighted medians of overall OBS, lifestyle OBS, and dietary OBS were 20, 4, and 16, respectively (Supplementary Table S3).

Lifestyle and dietary OBS associations with SII/SIRI levels

Table 2 shows the relationships between lifestyle OBS, dietary OBS, and SII/SIRI levels. In Model 1 (without any adjustments), OBS was negatively correlated with SII [$\beta = -4.55$, 95% Confidence Interval (CI): -5.921 to -3.177, p < 0.001], implying that SII decreases with increasing OBS. Furthermore, OBS was negatively correlated with SIRI levels ($\beta = -0.005$, 95%CI: -0.008 to -0.002, p = 0.002). In Model 2 (adjusted for age, sex, and race), both the negative associations between OBS and SII ($\beta = -3.62$, 95%CI: -5.004 to -2.232, p < 0.001) and between OBS and SIRI remained significant $(\beta = -0.009, 95\%$ CI: -0.012 to -0.005, p < 0.001). Similarly, in Model 3 (adjusted further for energy intake), the negative OBS-SII correlation remained significant ($\beta = -5.36, 95\%$ CI: -6.824 to -3.900, p < 0.001). Subgroup analyses of age, sex, and education (Supplementary Tables S4, S5) revealed a significantly negative correlation between OBS scores and SII/SIRI levels after correction using Model III. In SA, excluding any of the OBS components had no significant effect on the WLRA results of SII and SIRI (Supplementary Tables S6, S7).

Analyses of the correlations of both lifestyle OBS and dietary OBS with SII/SIRI yielded similar results. Overall, there was a significant negative correlation between OBS and SII levels, and the observed improvements in OBS values could be associated with a reduction in the immune-inflammatory state. This association remained significant after adjusting for covariates, including age, gender, race, and energy intake. These findings significantly enhance our understanding of the biological associations of oxidative homeostasis, systemic inflammatory responses, and immune inflammation.

Correlations of both lifestyle OBS and dietary OBS with SII/SIRI levels

The potential non-linear association between OBS and SII/SIRI levels was further examined through RCS analysis. Figure 2 shows a fully adjusted linear regression model (Model 3), adjusted for age, sex, race, and energy intake, and demonstrates a significant linear trend of both lifestyle OBS and dietary OBS with SII/SIRI levels (overall p<0.0001). Notably, non-linear trends did not show a significant p-value (non-linear p>0.05) (Figure 3).

Associations of both lifestyle OBS and dietary OBS with CVD in the high and low SII/SIRI groups

Based on Model 3, the LRA of OBS and participants with CVD revealed that in the ungrouped cohort, OBS was associated with a

TABLE 1 Baseline characteristics of quartiles from NHANES 2007–2018.

	ALL	Group 1 (<=15)	Group 2 (15–24)	Group 3 (> = 24)	<i>p</i> -value
	N = 9,451	N = 2,687	<i>N</i> = 4,308	<i>N</i> = 2,456	
Gender (%)					
Woman	3,961 (43.2)	1,513 (59.4)	1824 (44.9)	624 (25.9)	<0.001
Man	5,490 (56.8)	1,174 (40.6)	2,484 (55.1)	1832 (74.1)	
Age	39.00 [27.00, 53.00]	38.00 [27.00, 51.33]	40.00 [28.00, 54.00]	38.00 [27.00, 53.00]	0.004
Race (%)		·			
Mexican American	1,269 (8.0)	327 (8.1)	581 (7.7)	361 (8.3)	<0.001
Other Hispanic	810 (5.1)	230 (5.3)	385 (5.4)	195 (4.6)	
Non-Hispanic White	4,025 (66.6)	1,038 (62.0)	1837 (66.5)	1,150 (70.9)	
Non-Hispanic Black	2,231 (12.5)	854 (18.3)	966 (11.9)	411 (8.2)	
Other Race	1,116 (7.8)	238 (6.3)	539 (8.6)	339 (8.1)	
Education (%)					
\leq High school education	3,909 (37.4)	1,312 (48.5)	1727 (35.9)	870 (30.0)	<0.001
\geq High school education	5,199 (62.6)	1,250 (51.5)	2,433 (64.1)	1,516 (70.0)	
HDL	1.32 [1.09–1.60]	1.29 [1.06-1.58]	1.32 [1.09–1.60]	1.34 [1.09-1.60]	0.184
TC	4.86 [4.22-5.61]	4.89 [4.22-5.61]	4.91 [4.24-5.64]	4.78 [4.19-5.53]	0.056
PLT	238.00 [204.00-279.00]	251.00 [214.00-292.61]	238.00 [204.00-279.00]	229.00 [197.87-267.00]	<0.001
NEU	4.10 [3.10-5.20]	4.30 [3.40-5.50]	4.10 [3.20-5.20]	3.80 [3.00-4.90]	<0.001
LYM	2.10 [1.70-2.60]	2.20 [1.80-2.70]	2.10 [1.70-2.60]	2.00 [1.70-2.50]	<0.001
MONO	0.50 [0.40-0.70]	0.50 [0.40-0.70]	0.50 [0.40-0.70]	0.50 [0.40-0.70]	0.798
WBC	7.10 [5.90-8.50]	7.40 [6.10-9.00]	7.10 [5.90-8.50]	6.80 [5.60-8.10]	<0.001
RBC	4.76 [4.43-5.08]	4.68 [4.36-5.03]	4.74 [4.41-5.08]	4.84 [4.52-5.12]	<0.001
CVD (%)		l	'		'
No	6,142 (68.7)	1,663 (68.0)	2,783 (66.8)	1,696 (72.4)	<0.001
Yes	3,309 (31.3)	1,024 (32.0)	1,525 (33.2)	760 (27.6)	
Hypertension (%)		·	'		'
No	6,287 (70.2)	1708 (69.4)	2,853 (68.6)	1726 (73.5)	0.001
Yes	3,164 (29.8)	979 (30.6)	1,455 (31.4)	730 (26.5)	
CHF (%)		·	'		'
No	8,951 (98.7)	2,511 (98.6)	4,091 (98.6)	2,349 (99.0)	0.516
Yes	146 (1.3)	48(1.4)	66(1.4)	32(1.0)	
CAD (%)		·	·		
No	8,889 (98.1)	2,493 (98.4)	4,067 (97.9)	2,329 (98.1)	0.591
Yes	200 (1.9)	62 (1.6)	87 (2.1)	51 (1.9)	
AP (%)		·			
No	8,941 (98.6)	2,507 (98.5)	4,082 (98.4)	2,352 (98.9)	0.385
Yes	154 (1.4)	53 (1.5)	72 (1.6)	29 (1.1)	
MI (%)					
No	8,871 (97.8)	2,485 (97.7)	4,060 (97.7)	2,326 (98.1)	0.689
Yes	226 (2.2)	72 (2.3)	99 (2.3)	55 (1.9)	
Stroke (%)		·			
No	8,950 (98.7)	2,501 (98.3)	4,089 (98.5)	2,360 (99.2)	0.052
Yes	154 (1.3)	60 (1.7)	70 (1.5)	24 (0.8)	
SII	453.52 [333.79, 619.67]	484.43 [351.51, 672.75]	454.91 [335.20, 623.46]	420.12 [318.97, 570.00]	<0.001
SIRI	1.02 [0.72–1.47]	1.05 [0.74–1.52]	1.02 [0.71-1.49]	1.00 [0.72–1.41]	0.04

TABLE 2 Correlation analysis between lifestyle OBS, dietary OBS, and SII/SIRI levels.

	OBS components	Model 1	<i>p</i> -value	Model 2	<i>p</i> -value	Model 3	<i>p</i> -value
		β(95%CI)		β(95%CI)		β(95%CI)	
	OBS	-4.55 (-5.921, -3.177)	< 0.001	-3.62 (-5.004, -2.232)	<i>p</i> < 0.001	-5.36 (-6.824, -3.900)	< 0.001
SII	Lifestyle OBS	-23.53 (-30.21, -16.85)	< 0.001	-23.57 (-30.25, -16.89)	<i>p</i> < 0.001	-23.56 (-30.23, -16.89)	< 0.001
	Dietary OBS	-3.87 (-5.272, -2.474)	< 0.001	-2.79 (-4.240, -1.342)	<i>p</i> < 0.001	-4.32 (-5.930, -2.711)	< 0.001
	OBS	-0.005 (-0.008, -0.002)	0.002	-0.009 (-0.012, -0.005)	<i>p</i> < 0.001	-0.013 (-0.017, -0.010)	< 0.001
SIRI	Lifestyle OBS	-0.074 (-0.091, -0.057)	< 0.001	-0.070 (-0.087, -0.054)	<i>p</i> < 0.001	-0.070 (-0.087, -0.054)	< 0.001
	Dietary OBS	-0.002 (-0.005, 0.001)	0.264	-0.006 (-0.009, -0.002)	0.001	-0.010 (-0.013, -0.006)	< 0.001

Model 1: Crude with no adjustments.

Model 2: Adjusted for age, gender, and race.

Model 3: Adjusted for age, gender, race, and energy intake.



lower hypertension [Odds Ratio (OR): 0.954, 95%CI: 0.939–0.969, p < 0.001] and stroke(OR: 0.946, 95%CI: 0.907–0.987, p = 0.011) incidence (Figure 3). On the other hand, compared with dietary OBS, CAD (OR: 0.794, 95%CI: 0.685–0.919, p = 0.002), hypertension (OR: 0.738, 95%CI: 0.703–0.755, p < 0.001), CHF (OR: 0.736, 95%CI: 0.596–0. 909, p = 0.005), MI (OR: 0.785, 95%CI: 0.674–0.915, p = 0.002), and stroke (OR: 0.807, 95%CI: 0.667–0.978, p = 0.029) had lower incidences in lifestyle OBS (Figures 4, 5). After grouping subjects based on weighted SII/SIRI medians, we found significant SIRI and SII interactions in the OBS-CHF (*P* for interaction < 0.001) and OBS-MI (*P* for interaction = 0.023) relationships, respectively.

Similar results were found for dietary OBS, except that the *p*-value for the latter interaction was 0.049. No significant interaction was observed for SII/SIRI in the relationship between lifestyle OBS and CVD (Figures 4, 5).

Discussion

This study revealed that participants with higher OBS scores had better health and socioeconomic statuses than those with lower scores. Specifically, higher scores were associated with a lower CVD

Subgroups	OR(95CI%)			P.Value	P for interaction
AP	0.956(0.910-1.004)			0.07	
High_SII	0.966(0.888-1.051)			0.418	0.184
Low_SII	0.943(0.889-1.000)			0.048	
High_SIRI	0.963(0.900-1.030)		-	0.266	0.438
Low_SIRI	0.949(0.882-1.021)		-	0.16	
CAD	0.976(0.938-1.105)		-	0.225	
High_SII	0.992(0.926-1.061)			0.805	0.402
Low_SII	0.961(0.926-0.998)	-8-		0.037	
High_SIRI	1.003(0.952-1.057)	-+	<u> </u>	0.906	0.12
Low_SIRI	0.920(0.875-0.967)			0.001	
Hypertension	0.954(0.939-0.969)	-		<0.001	
High_SII	0.951(0.928-0.975)	-		<0.001	0.372
Low_SII	0.959(0.939-0.979)	-		<0.001	
High_SIRI	0.947(0.927-0.968)	-		<0.001	0.917
Low_SIRI	0.965(0.945-0.984)	-		0.001	
CHF	0.953(0.905-1.003)			0.066	
High_SII	1.006(0.934-1.084)		—	0.876	0.077
Low_SII	0.900(0.842-0.963)			0.002	
High_SIRI	0.994(0.935-1.057)		_	0.851	<0.001
Low_SIRI	0.891(0.828-0.958)			0.002	
MI	0.965(0.929-1.003)			0.07	
High_SII	0.984(0.924-1.048)		-	0.612	0.023
Low_SII	0.944(0.906-0.984)			0.006	
High_SIRI	1.005(0.956-1.057)		-	0.84	0.063
Low_SIRI	0.897(0.860-0.937)			<0.001	
Stroke	0.946(0.907-0.987)			0.011	
High_SII	0.959(0.889-1.033)		-	0.265	0.168
Low_SII	0.930(0.888-0.975)			0.003	
High_SIRI	0.945(0.883-1.012)			0.104	0.489
Low_SIRI	0.948(0.903-0.995)			0.031	
	0	.8 1	1	.2	
		⊲ Low risk	High Ris	-⊳ k	

incidence, confirming the correlation between OBS and CVD risk observed in previous research (15).

To the best of our knowledge, this was the first study to examine the relationship between OBS and SII/SIRI levels. It has been established that OBS reflects the body's oxidant-antioxidant balance, and disrupting this equilibrium could cause inflammation. For instance, Lakkur et al. found some correlation between OBS and cardiovascular inflammatory markers, particularly C-Reactive Protein (CRP) and White Blood Cell (WBC) count (27). Additionally, Lee and Park discovered that the OBS was negatively correlated with the levels of inflammatory markers (12).

Subgroups	OR(95Cl%)			P.Value	P for interaction
AP	0.866(0.736-1.020)		-	0.085	
High_SII	0.797(0.643-0.987)			0.038	0.133
Low_SII	0.937(0.708-1.239)			0.643	
High_SIRI	0.892(0.728-1.093)		_	0.268	0.753
Low_SIRI	0.877(0.607-1.268)			0.482	
CAD	0.794(0.685-0.919)			0.002	
High_SII	0.752(0.598-0.946)			0.016	0.723
Low_SII	0.825(0.692-0.984)			0.033	
High_SIRI	0.894(0.735-1.087)		_	0.258	0.817
Low_SIRI	0.641(0.520-0.791)			<0.001	
Hypertension	0.738(0.703-0.755)	-		<0.001	
High_SII	0.731(0.683-0.783)	•		<0.001	0.695
Low_SII	0.748(0.695-0.805)	+		<0.001	
High_SIRI	0.723(0.673-0.777)	•		<0.001	0.406
Low_SIRI	0.765(0.703-0.832)	-		<0.001	
CHF	0.736(0.596-0.909)			0.005	
High_SII	0.769(0.607-0.975)			0.031	0.283
Low_SII	0.689(0.495-0.958)			0.027	
High_SIRI	0.843(0.663-1.072)	_=	_	0.161	0.916
Low_SIRI	0.594(0.390-0.905)			0.016	
MI	0.785(0.674-0.915)			0.002	
High_SII	0.742(0.592-0.931)			0.011	0.341
Low_SII	0.819(0.667-1.005)			0.056	
High_SIRI	0.872(0.711-1.070)		_	0.188	0.566
Low_SIRI	0.666(0.502-0.884)			0.005	
Stroke	0.807(0.667-0.978)			0.029	
High_SII	0.796(0.639-0.991)			0.042	0.786
Low_SII	0.809(0.580-1.130)		_	0.211	
High_SIRI	0.798(0.648-0.982)			0.033	0.349
Low_SIRI	0.823(0.582-1.162)			0.265	
	0.	3 1	1.	7	
		⊲ Low risk	High Ris	⊳ k	
S vs. CVD LRA in the SII/SIRI	cohort.	2011 1101			

Consistent with these findings, our study revealed that OBS still had a significant negative correlation with SII/SIRI levels after adjusting for covariates such as age, sex, and ethnicity/race.

Using two novel OBS scoring methods, Hernández-Ruiz et al. assessed pro- and antioxidants and their interactions with individuals' oxidative balance based on dietary and lifestyle factors (28). A slightly similar approach was employed in this study. According to the results, lifestyle OBS and dietary OBS exhibited a significant negative correlation with SII. In the crude model (Model 1), only lifestyle OBS was significantly negatively correlated with SIRI, whereas the negative correlation between Dietary OBS and SIRI was not significant. After controlling for covariates such as age,

AP 0.960(0.912-1.011) → 0.118 High_SII 0.980(0.889-1.069) → 0.651 0.303 Low_SIR 0.980(0.880-1.025) → 0.325 0.293 Low_SIR 0.990(0.948-1.037) → 0.182 CAD 0.992(0.948-1.037) → 0.182 CAD 0.992(0.948-1.037) → 0.182 CAD 0.992(0.948-1.027) → 0.185 High_SIRI 1.015(0.92-1.093) → 0.655 0.14 Low_SIR 0.971(0.930-1.015) → 0.058 0.014 Hypertension 0.972(0.955-0.989) → 0.023 0.452 Low_SIR 0.996(0.943-0.989) → 0.005 0.872 Low_SIR 0.996(0.943-0.989) → 0.005 0.872 Low_SIR 0.996(0.942-1.125) → 0.518 0.112 Low_SIR 0.996(0.937-1.022) → 0.518 0.112 Low_SIR 0.915(0.857-0.976) → 0.008 High_SIR 1.029(0.942-1.125) → 0.518 0.112 Low_SIR </th <th>s</th> <th>Subgroups</th> <th>OR(95Cl%)</th> <th></th> <th></th> <th>P.Value</th> <th>P for interaction</th>	s	Subgroups	OR(95Cl%)			P.Value	P for interaction
High_SII 0.980(0.899-1.069) → 0.651 0.363 Low_SIR 0.938(0.884-0.995) → 0.033 High_SIR 0.967(0.903-1.035) → 0.325 0.293 Low_SIR 0.992(0.948-1.037) → 0.711 High_SII 1.015(0.942-1.093) → 0.668 0.481 Low_SIR 0.991(0.930-1.015) → 0.195 + High_SIR 1.013(0.957-1.072) → 0.655 0.14 Low_SIR 0.941(0.884-1.002) → 0.0058 + Hypertension 0.972(0.955-0.989) + 0.023 0.452 Low_SIR 0.996(0.943-0.998) + 0.005 0.872 Low_SIR 0.996(0.942-0.998) + 0.005 0.872 Low_SIR 0.980(0.959-1.001) + 0.006 + High_SIR 1.029(0.942-1.125) → 0.518 0.112 Low_SIR 0.980(0.939-1.022) + 0.312 + High_SIR 1.008(0.941-1.08) → 0.818 <0.001	Δ	١P	0.960(0.912-1.011)		-	0.118	
Low_SII 0.938(0.884-0.995) High_SIRI 0.967(0.903-1.035) CAD 0.992(0.988-1.025) CAD 0.992(0.988-1.025) CAD 0.992(0.988-1.037) High_SIRI 1.015(0.942-1.093) CAD 0.971(0.930-1.015) High_SIRI 1.013(0.957-1.072) High_SIRI 1.013(0.957-1.072) Hypertension 0.972(0.955-0.989) Hypertension 0.972(0.955-0.989) Hypertension 0.972(0.955-0.989) CHF 0.960(0.943-0.996) CHF 0.971(0.917-1.029) CHF 0.971(0.917-1.029) CHF 0.971(0.917-1.029) MI 0.980(0.939-1.001) CHF 0.915(0.857-0.976) MI 0.980(0.939-1.021) MI 0.980(0.939-1.021) MI 0.980(0.939-1.022) MI 0.925(0.883-0.979) MI 0.925(0.883-0.979) MI 0.925(0.883-0.979) MI 0.925(0.883-0.979) MI 0.9232 0.622 Low_SIR 0.955(0.883-0.979) MI 0.955(0.883-0.970) MI 0.955(0.883-0.970) MI 0.955(0.883-0.970) MI 0.955(0.983-0.970) MI 0.955(0.983-0.970		High_SII	0.980(0.899-1.069)			0.651	0.363
High_SIRI 0.967(0.903-1.035) → 0.325 0.293 Low_SIRI 0.950(0.880-1.025) → 0.182 CAD 0.992(0.948-1.037) → 0.711 High_SII 1.015(0.942-1.093) → 0.698 0.481 Low_SII 0.971(0.930-1.015) → 0.195 + High_SIRI 1.013(0.957-1.072) → 0.655 0.14 Low_SIRI 0.941(0.884-1.002) → 0.058 Hypertension 0.972(0.955-0.989) → 0.001 High_SIRI 0.960(0.943-0.998) → 0.032 Low_SIRI 0.960(0.943-0.989) → 0.032 High_SIRI 0.960(0.942-0.125) → 0.518 Low_SIRI 0.991(0.857-0.976) → 0.008 High_SIRI 1.029(0.942-1.125) → 0.518 0.112 Low_SIRI 0.912(0.845-0.984) → 0.019 ↓ MI 0.980(0.939-1.022) → 0.339 ↓ High_SIRI 1.018(0.865-1.074) → 0.511 0.07 Low_SIRI <t< td=""><td></td><td>Low_SII</td><td>0.938(0.884-0.995)</td><td></td><td></td><td>0.033</td><td></td></t<>		Low_SII	0.938(0.884-0.995)			0.033	
Low_SIRI 0.950(0.880-1.025) CAD 0.992(0.948-1.037) 0.711 High_SII 1.015(0.942-1.093) 0.698 0.481 Low_SII 0.971(0.930-1.015) 0.195 High_SII 1.013(0.957-1.072) 0.65 0.14 Low_SIRI 0.941(0.884-1.002) 0.058 Hypertension 0.972(0.955-0.989) 0.001 High_SII 0.966(0.943-0.998) 0.0023 0.452 Low_SIRI 0.966(0.943-0.998) 0.005 0.872 Low_SIRI 0.966(0.943-0.998) 0.005 0.872 Low_SIRI 0.966(0.943-0.989) 0.005 0.872 Low_SIRI 0.966(0.943-0.989) 0.005 0.872 Low_SIRI 0.960(0.943-0.989) 0.005 0.872 Low_SIRI 0.998(0.959-1.001) 0.066 CHF 0.971(0.917-1.029) 0.312 High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SIRI 0.912(0.845-0.984) 0.019 MI 0.980(0.939-1.022) 0.339 High_SIRI 1.008(0.941-1.08) 0.019 MI 0.980(0.939-1.022) 0.339 High_SIRI 1.018(0.965-1.074) 0.011 Low_SIRI 0.912(0.845-0.984) 0.019 Stroke 0.954(0.911-1.000) 0.049 High_SIRI 1.018(0.965-1.074) 0.049 High_SIRI 0.915(0.887-0.976) 0.001 Low_SIRI 0.912(0.888-1.030) 0.023 0.465 0.109 Low_SIRI 0.951(0.907-1.001) 0.0465 0.031 High_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1.2 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1.2 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1.2 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1.2 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1.2 Low_SIRI 0.955(0.907-1.001) 0.055 0.8 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2		High_SIRI	0.967(0.903-1.035)		_	0.325	0.293
CAD 0.992(0.948-1.037) 0.711 High_SII 1.015(0.942-1.093) 0.688 0.481 Low_SII 0.971(0.930-1.015) 0.195 High_SIR 1.013(0.957-1.072) 0.655 0.14 Low_SIR 0.941(0.884-1.002) 0.005 Hypertension 0.972(0.955-0.989) 0.001 High_SII 0.969(0.943-0.998) 0.002 0.023 0.452 Low_SII 0.976(0.954-0.998) 0.005 0.872 Low_SIR 0.980(0.959-1.001) 0.066 CHF 0.971(0.917-1.029) 0.312 High_SIR 1.029(0.942-1.125) 0.008 High_SIR 1.029(0.942-1.125) 0.008 High_SIR 1.029(0.942-1.125) 0.008 High_SIR 1.029(0.942-1.125) 0.008 High_SIR 1.008(0.941-1.08) 0.818 0.011 Low_SIR 0.980(0.939-1.022) 0.312 High_SIR 1.009(0.939-1.022) 0.319 High_SIR 1.009(0.941-1.07) 0.842 0.049 Low_SIR 0.912(0.845-0.984) 0.019 MI 0.980(0.939-1.022) 0.339 High_SIR 1.018(0.965-1.074) 0.011 Stroke 0.954(0.911-1.000) 0.049 High_SIR 1.018(0.965-1.074) 0.051 Stroke 0.954(0.911-1.000) 0.049 High_SIR 0.912(0.889-0.954) 0.031 High_SIR 0.912(0.899-1.050) 0.0465 0.109 Low_SIR 0.930(0.939-1.021) 0.065 Stroke 0.954(0.911-1.000) 0.049 High_SIR 0.912(0.899-1.050) 0.0465 0.109 Low_SIR 0.930(0.939-1.021) 0.050 0.82 1.2 Low_SIR 0.953(0.907-1.001) 0.055 0.82 1.2 0.82 1.2 0.82 1.2 0.82 1.2 0.82 1.2 0.82 1.2 0.83 1.2 0.84 1.2 0.84 1.2 0.84 1.2 0.84 1.2 0.84 1.2 0.84 1.2 0.84 1.2 0.84		Low_SIRI	0.950(0.880-1.025)		_	0.182	
CAD 0.992(0.948-1.037) - 0.711 High_SII 1.015(0.942-1.093) 0.698 0.481 Low_SII 0.971(0.930-1.015) 0.195 High_SIR 1.013(0.957-1.072) 0.65 0.14 Low_SIR 0.941(0.884-1.002) 0.058 Hypertension 0.972(0.955-0.989) 0.001 High_SII 0.969(0.943-0.996) 0.023 0.452 Low_SII 0.976(0.954-0.998) 0.005 0.872 Low_SIR 0.960(0.943-0.989) 0.005 0.872 Low_SIR 0.960(0.943-0.989) 0.005 0.872 Low_SIR 0.980(0.959-1.001) 0.06 CHF 0.971(0.917-1.029) 0.312 High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SIR 0.912(0.857-0.976) 0.008 High_SIR 1.008(0.941-1.08) 0.818 <0.001 Low_SIR 0.912(0.845-0.984) 0.019 MI 0.980(0.939-1.022) 0.339 High_SIR 1.007(0.941-1.07) 0.842 0.049 Low_SIR 0.912(0.845-0.984) 0.019 Stroke 0.954(0.911-1.000) 0.0511 0.07 Low_SIR 0.911(0.869-0.954) - <0.001 Stroke 0.954(0.911-1.000) 0.049 High_SIR 1.018(0.965-1.074) 0.5111 0.07 Low_SIR 0.911(0.869-0.954) - <0.001 Stroke 0.954(0.911-1.000) 0.049 High_SIR 0.912(0.848-1.030) 0.232 0.622 Low_SIR 0.953(0.907-1.001) 0.023 0.034 1.2 Low_SIR 0.953(0.907-1.001) 0.023 0.035 0.8 1 1.2 Low_SIR 0.953(0.907-1.001) 0.023 0.035 0.8 1 1.2 Low_SIR 0.953(0.907-1.001) 0.023 0.232 0.622 Low_SIR 0.953(0.907-1.001) 0.023 0.232 0.622 Low_SIR 0.951(0.907-1.001) 0.025 0.8 1 1.2 Low_risk High Risk							
High_SII 1.015(0.942-1.093) - 0.698 0.481 Low_SII 0.971(0.930-1.015) - 0.195 High_SIRI 1.013(0.957-1.072) - 0.65 0.14 Low_SIRI 0.941(0.884-1.002) - 0.058 Hypertension 0.972(0.955-0.989) - 0.001 High_SII 0.969(0.943-0.996) - 0.023 0.452 Low_SII 0.976(0.954-0.998) - 0.032 High_SIRI 0.966(0.943-0.989) - 0.032 Low_SIRI 0.980(0.959-1.001) - 0.06 CHF 0.971(0.917-1.029) - 0.312 High_SIRI 1.029(0.942-1.125) - 0.518 0.112 Low_SIRI 0.915(0.857-0.976) - 0.008 High_SIRI 1.008(0.941-1.08) - 0.8818 <0.001 Low_SIRI 0.912(0.845-0.984) - 0.019 High_SIRI 1.007(0.941-1.077) - 0.8422 0.049 Low_SIRI 0.912(0.845-0.984) - 0.011 High_SIRI 1.018(0.965-1.074) - 0.511 0.07 Low_SIRI 0.911(0.869-0.954) - <0.001 Stroke 0.954(0.911-1.000) - 0.046 0.109 Low_SIRI 0.912(0.899-1.050) - 0.004 High_SIRI 0.972(0.899-1.050) - 0.046 0.109 Low_SIRI 0.935(0.893-0.979) - 0.004 High_SIRI 0.935(0.893-0.979) - 0.004 High_SIRI 0.935(0.893-0.979) - 0.004 High_SIRI 0.956(0.888-1.030) - 0.232 0.622 Low_SIRI 0.953(0.907-1.001) - 0.055 0.8 1 1.2 Low_SIRI 0.953(0.907-1.001) - 0.055 0.8 1 1.2 0.8	C	CAD	0.992(0.948-1.037)		_	0.711	
Low_SII 0.971(0.930-1.015) - 0.195 High_SIRI 1.013(0.957-1.072) 0.65 0.14 Low_SIRI 0.941(0.884-1.002) 0.058 Hypertension 0.972(0.955-0.989) 0.001 High_SII 0.969(0.943-0.998) 0.023 0.452 Low_SII 0.976(0.954-0.998) 0.032 High_SIRI 0.966(0.943-0.989) 0.032 High_SIRI 0.980(0.959-1.001) 0.06 CHF 0.971(0.917-1.029) 0.312 High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SIRI 0.991(0.947-1.029) 0.312 High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SIRI 0.915(0.857-0.976) 0.008 High_SIRI 1.008(0.941-1.08) 0.818 <0.001 Low_SIRI 0.912(0.845-0.984) 0.031 High_SII 1.007(0.941-1.07) 0.842 0.049 Low_SIRI 0.912(0.845-0.984) 0.031 High_SII 1.007(0.941-1.07) 0.842 0.049 Low_SIRI 0.911(0.869-0.954) - 0.031 High_SII 0.951(0.909-0.995) 0.031 High_SIRI 0.912(0.845-0.984) 0.019 Low_SIRI 0.911(0.869-0.954) - 0.046 High_SII 0.972(0.899-1.050) 0.465 0.109 Low_SIRI 0.912(0.845-0.974) 0.049 High_SIRI 0.912(0.845-0.984) 0.022 0.622 Low_SIRI 0.911(0.869-0.954) - 0.023 High_SIRI 0.950(0.838-0.979) 0.004 High_SIRI 0.950(0.838-0.979) 0.004 High_SIRI 0.950(0.888-0.904) 0.045 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 0.8		High_SII	1.015(0.942-1.093)		-	0.698	0.481
High_SIRI 1.013(0.957-1.072) 0.65 0.14 Low_SIRI 0.941(0.884-1.002) 0.058 Hypertension 0.972(0.955-0.989) 0.001 High_SII 0.969(0.943-0.996) 0.023 0.452 Low_SII 0.976(0.954-0.998) 0.005 0.872 Low_SIRI 0.966(0.943-0.989) 0.005 0.872 Low_SIRI 0.980(0.959-1.001) 0.055 CHF 0.971(0.917-1.029) 0.012 High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SII 0.915(0.857-0.976) 0.008 High_SIRI 1.008(0.941-1.08) 0.818 <0.001 Low_SIRI 0.912(0.845-0.984) 0.019 MI 0.980(0.939-1.022) 0.339 High_SIRI 1.007(0.941-1.077) 0.8422 0.049 Low_SIRI 0.912(0.845-0.984) 0.019 Stroke 0.954(0.911-1.000) 0.031 High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) 0.001 Stroke 0.954(0.911-1.000) 0.049 High_SIRI 0.972(0.899-1.050) 0.0465 0.109 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 0.8 1		Low_SII	0.971(0.930-1.015)		-	0.195	
Low_SIRI 0.941(0.884-1.002) - 0.058 Hypertension 0.972(0.955-0.989) 0.001 High_SII 0.969(0.943-0.996) 0.023 0.452 Low_SII 0.976(0.954-0.998) 0.032 0.452 Low_SIRI 0.966(0.943-0.989) 0.005 0.872 Low_SIRI 0.980(0.959-1.001) - 0.66 CHF 0.971(0.917-1.029) - 0.312 High_SIRI 1.029(0.942-1.125) - 0.518 0.112 Low_SIRI 0.915(0.857-0.976) - 0.008 - High_SIRI 1.008(0.939-1.022) - 0.339 - High_SIRI 1.008(0.939-1.022) - 0.339 - High_SIRI 1.007(0.941-1.077) 0.842 0.049 Low_SIRI 0.951(0.909-0.995) - 0.031 - High_SIRI 1.018(0.965-1.074) - 0.511 0.07 Low_SIRI 0.951(0.899-0.954) - 0.004 - High_SIRI 0.954(0.911-1.000) - 0.0465 0.109 Low_SIRI 0		High_SIRI	1.013(0.957-1.072)		-	0.65	0.14
Hypertension 0.972(0.955-0.989) • 0.001 High_SII 0.969(0.943-0.996) • 0.023 0.452 Low_SII 0.976(0.954-0.998) • 0.032 • High_SIRI 0.966(0.943-0.989) • 0.005 0.872 Low_SIRI 0.980(0.959-1.001) • 0.06 • CHF 0.971(0.917-1.029) • 0.312 • High_SII 1.029(0.942-1.125) • 0.518 0.112 Low_SII 0.915(0.857-0.976) • 0.008 • High_SIRI 1.008(0.939-1.022) • 0.312 • MI 0.980(0.939-1.022) • 0.339 • High_SIRI 1.007(0.941-1.077) • 0.842 0.049 Low_SIRI 0.911(0.869-0.954) • • 0.001 Stroke 0.954(0.911-1.000) • 0.049 • High_SIRI 0.030 • 0.004 • High_SIRI 0.956(0.888-1.030) • 0.232 0.622 Low_SIRI 0.956(0.888-1.030)		Low_SIRI	0.941(0.884-1.002)			0.058	
Hypertension 0.972(0.955-0.989) + 0.001 High_SII 0.969(0.943-0.996) + 0.023 0.452 Low_SII 0.976(0.954-0.998) + 0.005 0.872 High_SIRI 0.966(0.943-0.989) + 0.006 - CMF 0.971(0.917-1.029) + 0.312 - High_SII 1.029(0.942-1.125) - 0.518 0.112 Low_SII 0.915(0.857-0.976) - 0.008 - High_SIRI 1.008(0.941-1.08) - 0.818 <0.001							
High_SII 0.969(0.943-0.996) ● 0.023 0.452 Low_SII 0.976(0.954-0.998) ● 0.032 0.452 High_SIRI 0.966(0.943-0.989) ● 0.005 0.872 Low_SIRI 0.980(0.959-1.001) ● 0.06 ● CHF 0.971(0.917-1.029) ● 0.312 ● High_SII 1.029(0.942-1.125) ● 0.518 0.112 Low_SII 0.915(0.857-0.976) ● 0.008 ● High_SIRI 1.008(0.941-1.08) ● 0.818 <0.001	H	lypertension	0.972(0.955-0.989)	-		0.001	
Low_SII 0.976(0.954-0.998) • 0.032 High_SIRI 0.966(0.943-0.989) • 0.005 0.872 Low_SIRI 0.980(0.959-1.001) • 0.06 CHF 0.971(0.917-1.029) • 0.312 High_SII 1.029(0.942-1.125) • 0.518 0.112 Low_SII 0.915(0.857-0.976) • 0.008 High_SIRI 1.008(0.941-1.08) • 0.818 <0.001 Low_SIRI 0.912(0.845-0.984) • 0.019 MI 0.980(0.939-1.022) • 0.339 High_SII 1.007(0.941-1.077) • 0.842 0.049 Low_SII 0.951(0.909-0.995) • 0.031 High_SIRI 1.018(0.965-1.074) • 0.511 0.07 Low_SIRI 0.911(0.869-0.954) • <0.001 Stroke 0.954(0.911-1.000) • 0.049 High_SIRI 0.911(0.869-0.954) • <0.001 Stroke 0.954(0.911-1.000) • 0.465 0.109 Low_SIRI 0.935(0.893-0.979) • 0.004 High_SIRI 0.956(0.888-1.030) • 0.232 0.622 Low_SIRI 0.953(0.907-1.001) • 0.055 0.8 1 1.2 Low_risk High_Risk		High_SII	0.969(0.943-0.996)	-=-		0.023	0.452
High_SIRI 0.966(0.943-0.989) ● 0.005 0.872 Low_SIRI 0.980(0.959-1.001) ● 0.06 ● CHF 0.971(0.917-1.029) ● 0.312 ● High_SII 1.029(0.942-1.125) ● 0.518 0.112 Low_SII 0.915(0.857-0.976) ● 0.008 ● High_SIRI 1.008(0.941-1.08) ● 0.818 <0.001		Low_SII	0.976(0.954-0.998)	-8-		0.032	
Low_SIRI 0.980(0.959-1.001) 0.06 CHF 0.971(0.917-1.029) 0.312 High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SII 0.915(0.857-0.976) 0.008 0.001 High_SIRI 1.008(0.941-1.08) 0.818 <0.001		High_SIRI	0.966(0.943-0.989)	-=-		0.005	0.872
CHF 0.971(0.917-1.029) 0.312 High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SII 0.915(0.857-0.976) 0.008 High_SIRI 1.008(0.941-1.08) 0.818 <0.001 Low_SIRI 0.912(0.845-0.984) 0.019 MI 0.980(0.939-1.022) 0.339 High_SII 1.007(0.941-1.077) 0.842 0.049 Low_SII 0.951(0.909-0.995) 0 0.031 High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) 0.049 High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) 0.049 High_SIRI 1.018(0.965-1.074) 0.049 High_SIRI 0.911(0.869-0.954) 0.049 High_SIRI 0.911(0.869-0.954) 0.0465 0.109 Low_SIR 0.935(0.893-0.979) 0.004 High_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 Low risk High Risk		Low_SIRI	0.980(0.959-1.001)	-=		0.06	
CHF 0.971(0.917-1.029) - 0.312 High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SII 0.915(0.857-0.976) 0.008 High_SIRI 1.008(0.941-1.08) 0.818 <0.001 Low_SIRI 0.912(0.845-0.984) 0.019 MI 0.980(0.939-1.022) 0.339 High_SII 1.007(0.941-1.077) 0.842 0.049 Low_SII 0.951(0.909-0.995) 0.031 High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) - 0.011 Stroke 0.954(0.911-1.000) 0.049 High_SII 0.972(0.899-1.050) 0.465 0.109 Low_SII 0.935(0.893-0.979) 0.004 High_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 Low risk High Risk							
High_SII 1.029(0.942-1.125) 0.518 0.112 Low_SII 0.915(0.857-0.976) 0.008 High_SIRI 1.008(0.941-1.08) 0.818 <0.001 Low_SIRI 0.912(0.845-0.984) 0.019 MI 0.980(0.939-1.022) 0.339 High_SII 1.007(0.941-1.077) 0.842 0.049 Low_SII 0.951(0.909-0.995) 0.031 High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) 0.049 High_SII 0.972(0.899-1.050) 0.465 0.109 Low_SII 0.935(0.893-0.979) 0.0465 0.109 Low_SII 0.935(0.893-0.979) 0.0465 0.109 Low_SIRI 0.935(0.893-0.979) 0.004 High_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 Low risk High Risk	C	CHF	0.971(0.917-1.029)		_	0.312	
Low_SII 0.915(0.857-0.976) 0.008 High_SIRI 1.008(0.941-1.08) 0.818 <0.001 Low_SIRI 0.912(0.845-0.984) -0.019 MI 0.980(0.939-1.022) 0.339 High_SII 1.007(0.941-1.077) 0.842 0.049 Low_SII 0.951(0.909-0.995) -0.031 High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) <0.001 Stroke 0.954(0.911-1.000) - 0.049 High_SIRI 0.972(0.899-1.050) 0.465 0.109 Low_SII 0.935(0.893-0.979) - 0.004 High_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.953(0.907-1.001) - 0.055 0.8 1 1.2 Low_risk 1.012 Low_risk 1.012 Low_risk 1.012 Low_risk 1.012 Low_risk 1.012 Low_SIRI 0.951(0.907.1.001) - 0.055		High_SII	1.029(0.942-1.125)		•	0.518	0.112
High_SIRI 1.008(0.941-1.08) 0.818 <0.001		Low_SII	0.915(0.857-0.976)			0.008	
Low_SIRI 0.912(0.845-0.984) 0.019 MI 0.980(0.939-1.022) - 0.339 High_SII 1.007(0.941-1.077) 0.842 0.049 Low_SII 0.951(0.909-0.995) - 0.031 High_SIRI 1.018(0.965-1.074) - 0.511 0.07 Low_SIRI 0.911(0.869-0.954) - <0.001 Stroke 0.954(0.911-1.000) - 0.049 High_SII 0.972(0.899-1.050) - 0.465 0.109 Low_SII 0.935(0.893-0.979) - 0.004 High_SIRI 0.956(0.888-1.030) - 0.232 0.622 Low_SIRI 0.956(0.888-1.030) - 0.232 0.622 Low_SIRI 0.953(0.907-1.001) - 0.055 0.8 1 1.2 Cow risk High Risk		High_SIRI	1.008(0.941-1.08)			0.818	<0.001
MI 0.980(0.939-1.022) - 0.339 High_SII 1.007(0.941-1.077) 0.842 0.049 Low_SII 0.951(0.909-0.995) - 0.031 High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) - <0.001 Stroke 0.954(0.911-1.000) - 0.049 High_SII 0.972(0.899-1.050) 0.465 0.109 Low_SII 0.935(0.893-0.979) 0.004 High_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 Low risk High Risk		Low_SIRI	0.912(0.845-0.984)			0.019	
MI 0.980(0.939-1.022) 0.339 High_SII 1.007(0.941-1.077) 0.842 0.049 Low_SII 0.951(0.909-0.995) 0.031 High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) - <0.001							
High_SII 1.007(0.941-1.077) Low_SII 0.951(0.909-0.995) High_SIRI 1.018(0.965-1.074) Low_SIRI 0.911(0.869-0.954) Stroke 0.954(0.911-1.000) High_SII 0.972(0.899-1.050) Low_SII 0.935(0.893-0.979) Low_SII 0.956(0.888-1.030) Uous_SIRI 0.956(0.888-1.030) Uous_SIRI 0.956(0.888-1.030) Uous_SIRI 0.953(0.907-1.001) Uous_SIRI 0.	N	II	0.980(0.939-1.022)		-	0.339	
Low_SII 0.951(0.909-0.995) - 0.031 High_SIRI 1.018(0.965-1.074) - 0.511 0.07 Low_SIRI 0.911(0.869-0.954) - <0.001 Stroke 0.954(0.911-1.000) - 0.049 High_SII 0.972(0.899-1.050) - 0.465 0.109 Low_SII 0.935(0.893-0.979) - 0.004 High_SIRI 0.956(0.888-1.030) - 0.232 0.622 Low_SIRI 0.956(0.888-1.030) - 0.232 0.622 Low_SIRI 0.953(0.907-1.001) - 0.055 0.8 1 1.2 Low risk High Risk		High_SII	1.007(0.941-1.077)	_	-	0.842	0.049
High_SIRI 1.018(0.965-1.074) 0.511 0.07 Low_SIRI 0.911(0.869-0.954) 0.049 High_SII 0.972(0.899-1.050) 0.465 0.109 Low_SIII 0.935(0.893-0.979) 0.004 High_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1.2 Low risk High Risk 		Low_SII	0.951(0.909-0.995)			0.031	
Low_SIRI 0.911(0.869-0.954) - <0.001 Stroke 0.954(0.911-1.000) - 0.049 High_SII 0.972(0.899-1.050) - 0.465 0.109 Low_SII 0.935(0.893-0.979) - 0.004 High_SIRI 0.956(0.888-1.030) - 0.232 0.622 Low_SIRI 0.953(0.907-1.001) - 0.055 0.8 1 1.2 Low risk High Risk		High_SIRI	1.018(0.965-1.074)	_	•	0.511	0.07
Stroke 0.954(0.911-1.000) - 0.049 High_SII 0.972(0.899-1.050) - 0.465 0.109 Low_SII 0.935(0.893-0.979) - 0.004 High_SIRI 0.956(0.888-1.030) - 0.232 0.622 Low_SIRI 0.953(0.907-1.001) - 0.055		Low_SIRI	0.911(0.869-0.954)			<0.001	
Stroke 0.954(0.911-1.000) - 0.049 High_SII 0.972(0.899-1.050) - 0.465 0.109 Low_SII 0.935(0.893-0.979) - 0.004 High_SIRI 0.956(0.888-1.030) - 0.232 0.622 Low_SIRI 0.953(0.907-1.001) - 0.055 0.8 1 1.2 Low risk High Risk							
High_SII 0.972(0.899-1.050) • 0.465 0.109 Low_SII 0.935(0.893-0.979) • 0.004 High_SIRI 0.956(0.888-1.030) • 0.232 0.622 Low_SIRI 0.953(0.907-1.001) • 0.055 0.8 1 1.2 Low risk High Risk	S	Stroke	0.954(0.911-1.000)			0.049	
Low_SII 0.935(0.893-0.979) - 0.004 High_SIRI 0.956(0.888-1.030) 0.232 0.622 Low_SIRI 0.953(0.907-1.001) 0.055 0.8 1 1.2 Low risk High Risk IGURE 5 Dietary OBS vs. CVD LRA in the SII/SIRI cohort.		High_SII	0.972(0.899-1.050)		_	0.465	0.109
High_SIRI 0.956(0.888-1.030) Low_SIRI 0.953(0.907-1.001) 0.8 1 1.2 Low risk High		Low_SII	0.935(0.893-0.979)			0.004	
Low_SIRI 0.953(0.907-1.001) - 0.055 0.8 1 1.2 Low risk High Risk FIGURE 5 Dietary OBS vs. CVD LRA in the SII/SIRI cohort.		High_SIRI	0.956(0.888-1.030)		-	0.232	0.622
0.8 1 1.2 Low risk High Risk FIGURE 5 Dietary OBS vs. CVD LRA in the SII/SIRI cohort.		Low_SIRI	0.953(0.907-1.001)			0.055	
FIGURE 5 Dietary OBS vs. CVD LRA in the SII/SIRI cohort.			0.	8 1	1	.2	
FIGURE 5 Dietary OBS vs. CVD LRA in the SII/SIRI cohort.				Low risk	High Ris	k	
	FIGURE 5 Dietary OBS vs. CVD LR.	A in the SII/SIRI co	bhort.				

sex, race, and energy intake, the negative correlations of these scores with both SII and SIRI became even more significant. This phenomenon could be attributed to age and gender, among other factors affecting diet. Additionally, the SII levels of participants with different sexes, ages, and education levels showed significant negative correlations in each model, whereas SIRI showed contrasting results in the low-education and high-age groups (16). Furthermore, the RCS analysis further verified the association of lifestyle and dietary OBS with SII/SIRI, with a significant linear correlation between OBS and SII/SIRI levels.

In addition to observing the OBS scores, we also examined the effects of dietary and lifestyle OBS on CVD (10). Compared to dietary OBS, lifestyle OBS played a more crucial role in CVD. Furthermore, previous research linked higher OBS to reduced Ischemic Heart Disease (IHD) risk, especially AP and MI (29). Possible explanations are that the previous research included 21,867 individuals aged >20 years, whereas our study only involved 9,451 individuals and our regression analysis was adjusted for weight (30). The previous study also used seven cycles of the NHANES data, while we only used six cycles. Our findings revealed that overall and lifestyle OBS were negatively correlated with hypertension at different inflammatory index levels. Furthermore, previous Korean research showed that the incidence of new hypertension events correlated negatively with OBS in a dosedependent manner (12). Like Type 2 Diabetes Mellitus (T2DM), hypertension is also considered a chronic inflammatory disease (31). Consistent with previous studies on the relationship between new-onset hypertension and OBS, we found that antioxidant exposure in the OBS correlated negatively with hypertension incidence. Additionally, crosssectional studies on the interaction of SII and the Neutrophil-to-Lymphocyte Ratio (NLR) with hypertension revealed that SII and NLR were positively correlated with hypertension prevalence (13, 32).

Other diseases closely related to inflammation are MI and CHF. Consistent with the findings of Chen et al. on the effects of OBS and sleep patterns on CVD risk, we found no direct correlation between OBS and MI and CHF risk. Furthermore, Zhao et al. discovered a correlation between SII and Heart Failure (HF) prognosis (33). However, we conducted further analysis, revealing a significant interaction of SIRI in the relationship between overall OBS, dietary OBS, and CHF (*P for interaction* < 0.001). On the other hand, SII had a significant interaction in the relationship between overall OBS, dietary OBS, and MI (*P for interaction* < 0.05).

Previous research has shown that disrupting the pro-oxidantantioxidant balance could lead to OS, a mechanism underlying stroke occurrence (34). Specifically, brain ischemia induces oxygen-free radical damage in tissues, triggering a complex pathological process that involves various cytokines and signaling pathways. Therefore, developing new drugs and compounds with antioxidant properties for stroke treatment is imperative (35). Following prompt administration, antioxidants improved various outcome measures in some Ischemic Stroke (IS) models, such as transient middle cerebral artery occlusion. Herein, OBS, as an indicator of the oxidant-antioxidant exposure balance, strongly predicted the likelihood of stroke in different oxidative states. On the other hand, the dynamic states of SII and SIRI, as systemic inflammation indicators, were significantly associated with CVD risk (36). This deduction was not undoubtedly confirmed in our study, possibly due to its cross-sectional nature, but previous studies had compelling results as they conducted up to 8 years of follow-up and calculated Cox Hazard Ratios (HRs).

Using the NHANES data, this study examined the linear correlation between overall OBS, lifestyle OBS, dietary OBS, and SII/SIRI levels, as well as the protective and ameliorative relationships of OBS with CVD. Although this study offers novel insights into correlations between OBS and inflammation levels and between OBS and CVD, it had some limitations. This study used data from the NHANES project, a cross-sectional study. Consequently, it could not determine the causal relationships between overall OBS, lifestyle OBS, dietary OBS, and SII/ SIRI levels but only reflected the existing correlations. Therefore, we cannot overrule the influence of other potential confounding or mediating factors and the long-term effects of overall OBS, lifestyle OBS, and dietary OBS on SII/SIRI levels. Consequently, additional animal and molecular biology experiments are required to verify the mechanism underlying the significant negative correlation of OBS with SII/SIRI. Additionally, the participants were only from the US, necessitating additional multiregional, large cohort studies that take into account the particular circumstances and differences in different countries or regions to better elucidate the relationship between overall OBS, lifestyle OBS, dietary OBS, and CVD at different inflammation levels. Furthermore, the subjects included in the final analysis were only about one-fifth of the total population enrolled after implementing the selection criteria. Although these exclusion criteria satisfied this study's requirements, it still impacted the statistical validity of our findings.

Conclusion

Our study found that individuals with higher OBS, encompassing both lifestyle and dietary OBS, were associated with lower levels of SII and SIRI. Specifically, higher lifestyle OBS showed a more significant association with a reduced risk of CAD, hypertension, CHF, MI, and stroke compared to dietary OBS. These findings underscore the importance of maintaining a healthy lifestyle and dietary habits in reducing inflammation and lowering the risk of CVD.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

KC: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. SL: Conceptualization, Data curation, Investigation, Methodology, Supervision, Validation, Writing – review & editing, Formal analysis, Project administration, Software. ZX: Writing – review & editing. YiL: Methodology, Project administration, Software, Supervision, Validation, Writing – review & editing. YaL: Formal analysis, Project administration, Software, Supervision, Validation, Writing – review & editing. JM: Investigation, Methodology, Software, Supervision, Writing – review & editing. CL: Writing – review & editing. QW: Writing – review & editing. SZ: Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Natural Science Foundation of China (Nos. 82274016 and 81872934), the Science and Technology Program of Guangzhou (No. 2023B03J1251), the Key-Area Research and Development Program of Guangdong Province, China (No.

2019B020229003), and National Key Research and Development Program (No. 2017YFC0909301).

Acknowledgments

We extend our sincere appreciation to all of the participants and the devoted team of the NHANES for their substantial contributions and steadfast commitment.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and National Burden of cardiovascular diseases for 10 causes, 1990 to 2015. *J Am Coll Cardiol.* (2017) 70:1–25. doi: 10.1016/j.jacc.2017.04.052

2. Nd W. Epidemiological studies of CHD and the evolution of preventive cardiology. *Nat Rev Cardiol.* (2014) 11:276–89. doi: 10.1038/nrcardio.2014.26

3. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. *Lancet Neurol.* (2021) 20:795–820. doi: 10.1016/S1474-4422(21)00252-0

4. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European Society of Cardiology: cardiovascular disease statistics 2021. *Eur Heart J.* (2022) 43:716–99. doi: 10.1093/eurheartj/ehab892

5. Liu S, Li Y, Zeng X, Wang H, Yin P, Wang L, et al. Burden of cardiovascular diseases in China, 1990–2016: findings from the 2016 global burden of disease study. *JAMA Cardiol.* (2019) 4:342–52. doi: 10.1001/jamacardio.2019.0295

6. Annor FB, Goodman M, Okosun IS, Wilmot DW, Il'yasova D, Ndirangu M, et al. Oxidative stress, oxidative balance score, and hypertension among a racially diverse population. *J Am Soc Hypertens*. (2015) 9:592–9. doi: 10.1016/j.jash.2015.05.014

7. Thomas SR, Neuzil J, Mohr D, Stocker R. Coantioxidants make alpha-tocopherol an efficient antioxidant for low-density lipoprotein. *Am J Clin Nutr.* (1995) 62:1357S–64S. doi: 10.1093/ajcn/62.6.1357S

8. Kawada T. Oxidative stress markers and cardiovascular disease: advantage of using these factors in combination with lifestyle factors for cardiovascular risk assessment. *Int J Cardiol.* (2012) 157:119–20. doi: 10.1016/j.ijcard.2012.03.107

9. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, et al. Oxidative stress, aging, and diseases. *Clin Interv Aging*. (2018) 13:757–72. doi: 10.2147/CIA.S158513

10. Ilori TORo YS, Kong SY, Gutierrez OM, Ojo AO, Judd SE, et al. OXIDATIVE BALANCE SCORE AND CHRONIC KIDNEY DISEASE. *Am J Nephrol.* (2015) 42:320–7. doi: 10.1159/000441623

11. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. *Annu Rev Pharmacol Toxicol.* (2004) 44:239–67. doi: 10.1146/annurev.pharmtox.44.101802.121851

12. Lee J-H, Son D-H, Kwon Y-J. Association between oxidative balance score and new-onset hypertension in adults: a community-based prospective cohort study. *Front Nutr.* (2022) 9:1066159. doi: 10.3389/fnut.2022.1066159

13. Meng X, Chang Q, Liu Y, Chen L, Wei G, Yang J, et al. Determinant roles of gender and age on SII, PLR, NLR, LMR and MLR and their reference intervals defining in Henan, China: a posteriori and big-data-based. *J Clin Lab Anal*. (2017) 32:e22228. doi: 10.1002/jcla.22228

14. Xiao S, Wang Z, Zuo R, Zhou Y, Yang Y, Chen T, et al. Association of Systemic Immune Inflammation Index with all-cause, cardiovascular disease, and Cancer-related mortality in patients with cardiovascular disease: a cross-sectional study. *J Inflamm Res.* (2023) 16:941–61. doi: 10.2147/JIR.S402227

15. Chen X, Wang C, Dong Z, Luo H, Ye C, Li L, et al. Interplay of sleep patterns and oxidative balance score on total cardiovascular disease risk: insights from the National Health and nutrition examination survey 2005–2018. *J Glob Health*. 13:04170. doi: 10.7189/jogh.14.04170

16. Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: a 20-year follow-up cohort study of 42,875 US adults. *J Clin Med.* (2023) 12:1128. doi: 10.3390/jcm12031128

17. Kong F, Huang J, Xu C, Huang T, Wen G, Cheng W. System inflammation response index: a novel inflammatory indicator to predict all-cause and cardiovascular disease

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2024.1374992/ full#supplementary-material

mortality in the obese population. Diabetol Metab Syndr. (2023) 15:195. doi: 10.1186/ s13098-023-01178-8

18. Zheng H, Yin Z, Luo X, Zhou Y, Zhang F, Guo Z. Associations between systemic immunity-inflammation index and heart failure: evidence from the NHANES 1999–2018. *Int J Cardiol.* (2024) 395:131400. doi: 10.1016/j.ijcard.2023.131400

19. Boesing F, Patiño JSR, da Silva VRG, Moreira EAM. The interface between obesity and periodontitis with emphasis on oxidative stress and inflammatory response. *Obes Rev.* (2009) 10:290–7. doi: 10.1111/j.1467-789X.2008.00555.x

20. White PC, Chicca IJ, Cooper PR, Milward MR, Chapple ILC. Neutrophil extracellular traps in periodontitis: a web of intrigue. *J Dent Res.* (2016) 95:26–34. doi: 10.1177/0022034515609097

21. Lei X, Xu Z, Chen W. Association of oxidative balance score with sleep quality: NHANES 2007–2014. J Affect Disord. (2023) 339:435–42. doi: 10.1016/j.jad.2023.07.040

22. Zhang W, Peng S-F, Chen L, Chen H-M, Cheng X-E, Tang Y-H. Association between the oxidative balance score and telomere length from the National Health and nutrition examination survey 1999–2002. *Oxidative Med Cell Longev.* (2022) 2022:1345071–11. doi: 10.1155/2022/1345071

23. Hu B, Yang X-R, Xu Y, Sun Y-F, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res.* (2014) 20:6212–22. doi: 10.1158/1078-0432.CCR-14-0442

24. Cheng W, Bu X, Xu C, Wen G, Kong F, Pan H, et al. Higher systemic immuneinflammation index and systemic inflammation response index levels are associated with stroke prevalence in the asthmatic population: a cross-sectional analysis of the NHANES 1999–2018. *Front Immunol.* (2023) 14:1191130. doi: 10.3389/fimmu.2023.1191130

25. Cao Y, Li P, Zhang Y, Qiu M, Li J, Ma S, et al. Association of systemic immune inflammatory index with all-cause and cause-specific mortality in hypertensive individuals: results from NHANES. *Front Immunol.* (2023) 14:1087345. doi: 10.3389/fimmu.2023.1087345

26. Núñez E, Steyerberg EW, Núñez J. Regression modeling strategies. *Rev Esp Cardiol.* (2011) 64:501–7. doi: 10.1016/j.recesp.2011.01.019

27. Lakkur S, Judd S, Bostick RM, McClellan W, Flanders WD, Stevens VL, et al. Oxidative stress, inflammation, and markers of cardiovascular health. *Atherosclerosis*. (2015) 243:38–43. doi: 10.1016/j.atherosclerosis.2015.08.032

28. Hernández-Ruiz Á, García-Villanova B, Guerra-Hernández EJ, Carrión-García CJ, Amiano P, Sánchez M-J, et al. Oxidative balance scores (OBSs) integrating nutrient, food and lifestyle dimensions: development of the NutrientL-OBS and FoodL-OBS. *Antioxidants (Basel)*. (2022) 11:300. doi: 10.3390/antiox11020300

29. Cheng S, Han Y, Jiang L, Lan Z, Liao H, Guo J. Associations of oxidative balance score and visceral adiposity index with risk of ischaemic heart disease: a cross-sectional study of NHANES, 2005–2018. *BMJ Open.* (2023) 13:e072334. doi: 10.1136/bmjopen-2023-072334

30. Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszon-Moran D, Dohrmann SM, et al. National health and nutrition examination survey: analytic guidelines, 1999–2010. *Vital Health Stat* 2, (2013) 161 1–24. Available at: https://pubmed.ncbi.nlm.nih.gov/25090154/ (Accessed January 17, 2024).

31. Jesmin RMS, Jamil H, Hontecillas R, Bassaganya-Riera J. Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. *BMC Med Genet.* (2010) 3:45. doi: 10.1186/1755-8794-3-45

32. Xu J-P, Zeng R-X, Zhang Y-Z, Lin S-S, Tan J-W, Zhu H-Y, et al. Systemic inflammation markers and the prevalence of hypertension: a NHANES cross-sectional study. *Hypertens Res.* (2023) 46:1009–19. doi: 10.1038/ s41440-023-01195-0

33. Zhao Z, Zhang X, Sun T, Huang X, Ma M, Yang S, et al. Prognostic value of systemic immune-inflammation index in CAD patients: systematic review and meta-analyses. *Eur J Clin Investig.* (2023) 54:e14100. doi: 10.1111/eci.14100

34. Simani L, Ryan F, Hashemifard S, Hooshmandi E, Madahi M, Sahraei Z, et al. Serum coenzyme Q10 is associated with clinical neurological outcomes in acute stroke patients. *J Mol Neurosci.* (2018) 66:53–8. doi: 10.1007/s12031-018-1115-1 35. Wang J, Zhang W, Lv C, Wang Y, Ma B, Zhang H, et al. A novel biscoumarin compound ameliorates cerebral ischemia reperfusion-induced mitochondrial oxidative injury via Nrf2/Keap1/ARE signaling. *Neuropharmacology.* (2020) 167:107918. doi: 10.1016/j.neuropharm.2019.107918

36. Li J, He D, Yu J, Chen S, Wu Q, Cheng Z, et al. Dynamic status of SII and SIRI alters the risk of cardiovascular diseases: evidence from Kailuan cohort study. *J Inflamm Res.* (2022) 15:5945–57. doi: 10.2147/JIR.S378309